|
|
Volumn 18, Issue 12, 2000, Pages 1235-
|
|
Company, academics argue over data.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
HUMAN IMMUNODEFICIENCY VIRUS VACCINE;
ARTICLE;
BIOTECHNOLOGY;
DRUG INDUSTRY;
FINANCIAL MANAGEMENT;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
INTERPERSONAL COMMUNICATION;
LEGAL ASPECT;
ORGANIZATION AND MANAGEMENT;
PHASE 3 CLINICAL TRIAL;
PUBLISHING;
RESEARCH;
STANDARD;
TREATMENT OUTCOME;
UNITED STATES;
UNIVERSITY;
AIDS VACCINES;
BIOTECHNOLOGY;
CALIFORNIA;
CLINICAL TRIALS, PHASE III;
CONTRACT SERVICES;
DRUG INDUSTRY;
HIV INFECTIONS;
HUMANS;
MASSACHUSETTS;
NEGOTIATING;
PRIVATE SECTOR;
PUBLISHING;
RESEARCH;
RESEARCH SUPPORT;
TREATMENT OUTCOME;
UNIVERSITIES;
|
|
EID: 0034541009
PISSN: 10870156
EISSN: None
Source Type: Journal
DOI: 10.1038/82325 Document Type: Article |
|
Times cited : (5)
|
|
References (0)
|
